Since there is an ongoing debate over the cell of origin for gliomas with Nestin-expressing neural stem and progenitor cells (NSCs) and oligodendrocyte progenitor cells (OPCs) being the two major candidates to transform into tumor cells and to shape tumor heterogeneity, it is important to characterize the relative contribution of each population to glioma initiation and progression in the context of BRAFV600E mutation. The gene discussed is NES; the disease is central nervous system cancer.